Inbiomotion appoints Dr. David L. Lacey to its Board of Directors
Barcelona January 29, 2013 – Inbiomotion SL, a company focused on the development of a specific biomarker for the prediction of bone metastasis, has strengthened its board of directors with the appointment of Dr. David L. Lacey.
Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the human anti- RANKL monoclonal antibody denosumab, which was approved in 2010 by the U.S. Food and Drug Administration (FDA) under the trade name Prolia to treat osteoporosis in postmenopausal women and as Xgeva for the prevention of skeletal-related events in metastatic bone tumors. He was most recently responsible for leading more than 1,200 scientists in Amgen’s discovery research unit across a portfolio of discovery and preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience.
Since Dr. Lacey’s recent retirement, he remains active in the biopharmaceutical industry, advising a number of academic institutions, biotechnology companies and venture capital firms. Dr. Lacey holds an MD from the University of Colorado, USA, and carried out his postgraduate medical education training and research at Washington University, St. Louis, USA.
“The future of medicine depends, in part, on the development of predictive tests that guide the utilization of expensive, novel therapies. Inbiomotion’s specific biomarker identifying newly diagnosed cancer patients at skeletal risk for the development of metastatic disease represents part of that future. In addition, understanding the biologic pathway that this biomarker pinpoints may lead to the discovery of next generation therapies. I am very excited to join the Inbiomotion team” said Dr. Lacey.
“David is a recognized expert in bone metabolism, and notably one of the “fathers” of denosumab. We are pleased to have his insight and direction in our efforts to develop the first ever companion diagnostic in preventive treatment strategies for bone metastasis,” said Joël Jean-Mairet, Chairman of Inbiomotion and General Partner at Ysios Capital. “His unique perspective will help guide us as we seek to impact the clinical management and standard of care of early stage cancer patients prone to bone relapse.”
Inbiomotion SL, a spin-out company founded by Dr. Roger Gomis from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. The company is focused on the development of a specific biomarker for the prediction of bone metastasis from primary tumor biopsies. In July 2012 Inbiomotion closed a € 2 million Series A financing led by Ysios Capital. Inbiomotion’s proprietary single biomarker codes for a nuclear protein and is able to predict which patients will relapse to the bone. It has been initially validated with over 900 patient samples in two independent cohorts with three independent techniques (gene expression, IHC and ISH).
Cecilia Ducco, Inbiomotion
T +34 934 033 780